ペプチド治療薬の世界市場2019-2023

◆英語タイトル:Global Peptide Therapeutics Market 2019-2023
◆商品コード:IRTNTR30538
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月24日
◆ページ数:118
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、ペプチド治療薬の世界市場について調査・分析し、市場概要、市場環境、ペプチド治療薬市場規模、投与ルート別(非経口、経口)分析、適応別分析、技術別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・ペプチド治療薬の世界市場概要
・ペプチド治療薬の世界市場環境
・ペプチド治療薬の世界市場動向
・ペプチド治療薬の世界市場規模
・ペプチド治療薬の世界市場:業界構造分析
・ペプチド治療薬の世界市場:投与ルート別(非経口、経口)
・ペプチド治療薬の世界市場:適応別
・ペプチド治療薬の世界市場:技術別
・ペプチド治療薬の世界市場:地域別市場規模・分析
・ペプチド治療薬の北米市場規模・予測
・ペプチド治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・ペプチド治療薬のアジア太平洋市場規模・予測
・ペプチド治療薬の主要国分析
・ペプチド治療薬の世界市場:意思決定フレームワーク
・ペプチド治療薬の世界市場:成長要因、課題
・ペプチド治療薬の世界市場:競争環境
・ペプチド治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
One of the major drivers of the global peptide therapeutics market is the growing cases of chronic diseases such as cancer, diabetes, obesity, and various cardiovascular diseases. Peptides are known to have high efficacy in the treatment of these diseases. Hence the use of peptides has increased significantly in recent years with the growing prevalence of chronic conditions. The high prevalence of chronic conditions leads to significant demand for curative drugs such as peptides thereby driving market growth. Moreover, the significant need for the treatment of these diseases has led various pharmaceutical companies to develop therapies, including peptide-based drugs. Technavio’s analysts have predicted that the peptide therapeutics market will register a CAGR of almost 9% by 2023.
Market Overview
Novel drug delivery
Currently the treatment of various diseases with peptides is predominantly done by administering drugs through the parenteral route. The parenteral RoA is considered to be one of the most undesirable routes for patients due to the invasive nature of the drug administration. Hence. vendors are focusing on developing better drug delivery systems. The increasing need for novel drug delivery systems has led to the development of self-injectable pens by various vendors.
Stringent regulatory policies
One of the major challenges faced by the global peptide therapeutics market is the stringent policies set by regulatory bodies globally. The policies set for the approval of biologic drugs by regulatory bodies are more stringent than for small molecules, which makes it difficult for pharmaceutical companies to launch these drugs in the market. The late launch of drugs or FDA refusal of a drug can hinder the growth of the market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the peptide therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Parenteral – Market size and forecast 2018-2023
• Oral – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by RoA
PART 07: MARKET SEGMENTATION BY INDICATION
PART 08: MARKET SEGMENTATION BY TECHNOLOGY
PART 09: CUSTOMER LANDSCAPE
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceutical
PART 15: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: RoA – Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral – Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral – Year-over-year growth 2019-2023 (%)
Exhibit 24: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Market share by 2018-2023 (%)
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eli Lilly – Vendor overview
Exhibit 47: Eli Lilly – Business segments
Exhibit 48: Eli Lilly – Organizational developments
Exhibit 49: Eli Lilly – Geographic focus
Exhibit 50: Eli Lilly – Segment focus
Exhibit 51: Eli Lilly – Key offerings
Exhibit 52: Eli Lilly – Key customers
Exhibit 53: Novo Nordisk – Vendor overview
Exhibit 54: Novo Nordisk – Business segments
Exhibit 55: Novo Nordisk – Organizational developments
Exhibit 56: Novo Nordisk – Geographic focus
Exhibit 57: Novo Nordisk – Segment focus
Exhibit 58: Novo Nordisk – Key offerings
Exhibit 59: Novo Nordisk – Key customers
Exhibit 60: Sanofi – Vendor overview
Exhibit 61: Sanofi – Business segments
Exhibit 62: Sanofi – Organizational developments
Exhibit 63: Sanofi – Geographic focus
Exhibit 64: Sanofi – Segment focus
Exhibit 65: Sanofi – Key offerings
Exhibit 66: Sanofi – Key customers
Exhibit 67: Takeda Pharmaceutical – Vendor overview
Exhibit 68: Takeda Pharmaceutical – Business segments
Exhibit 69: Takeda Pharmaceutical – Organizational developments
Exhibit 70: Takeda Pharmaceutical – Geographic focus
Exhibit 71: Takeda Pharmaceutical – Key offerings
Exhibit 72: Takeda Pharmaceutical – Key customers
Exhibit 73: Teva Pharmaceutical – Vendor overview
Exhibit 74: Teva Pharmaceutical – Business segments
Exhibit 75: Teva Pharmaceutical – Organizational developments
Exhibit 76: Teva Pharmaceutical – Geographic focus
Exhibit 77: Teva Pharmaceutical – Segment focus
Exhibit 78: Teva Pharmaceutical – Key offerings
Exhibit 79: Teva Pharmaceutical – Key customers
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations



【掲載企業】

Eli Lilly、Novo Nordisk、Sanofi、Takeda Pharmaceutical、Teva Pharmaceutical

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ペプチド治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆